Evidence analysisNovember 16, 2026Health & Science
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Date of authorisation: 24/09/2025, Revision: 3, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Kisunla, containing the active substance donanemab, is an approved medicine in the European Union for treating adults with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. It is authorized specifically for patients with none or only one copy of the apolipoprotein E4 (ApoE4) gene and who show evidence of abnormal amyloid beta protein deposits in the brain.
Kisunla is given intravenously once every four weeks and treatment should not exceed 18 months. Its mechanism of action involves targeting amyloid beta plaques in the brain. Donanemab is a monoclonal antibody that binds amyloid beta and recruits the brain’s immune cells to clear these toxic protein accumulations, which are believed to disrupt normal brain function in Alzheimer’s disease.
Clinical evidence from a randomized controlled trial with 1,736 patients demonstrated that after 18 months, those treated with Kisunla experienced a smaller decline in cognitive and functional abilities as measured by the integrated Alzheimer’s Disease Rating Scale (iADRS) compared to those receiving placebo. The average worsening was 11 points versus 13 points respectively.
Side effects are common and include brain swelling and bleeding (amyloid-related imaging abnormalities—ARIA), headache, and infusion-related reactions. Patients require multiple MRI scans before and during treatment to monitor for ARIA. Kisunla is contraindicated in patients with uncontrolled bleeding disorders, severe brain white matter disease, or those unable to have MRI scans.
What the source claims
- The European Medicines Agency (EMA) asserts that Kisunla’s benefits outweigh its risks for the specified patient population, which has led to its authorization across the EU.
- The risk of serious side effects such as ARIA is reduced in patients with none or one copy of the ApoE4 gene, making targeted genetic screening a critical part of patient selection.
- The medicine must be administered only in specialized settings by experienced doctors and healthcare teams who can detect, monitor, and manage ARIA and infusion reactions.
- Continuous safety monitoring and risk minimization measures are included. These measures involve controlled healthcare access programs, patient and healthcare provider education on ARIA, and ongoing data collection from an EU patient registry.
- Kisunla reduces cognitive decline at a statistically significant level but with modest clinical effect, as the difference on iADRS was 2 points over 18 months (11 vs 13 points decline).
What may be missing from the usual framing
The EMA documentation does not elaborate on the long-term clinical significance of the modest slowing of decline observed with Kisunla. The reported 2 point difference on the iADRS over 18 months, while statistically significant, may have limited impact on quality of life or daily functioning for some patients and caregivers.
The necessity of frequent MRI scans and monitoring for ARIA is described as part of routine care, but the burden, costs, and accessibility of such monitoring in real-world settings require further discussion. This is especially relevant given ARIA can be asymptomatic yet potentially serious.
Information on what happens after the 18-month treatment window is limited, raising questions about disease progression once treatment stops and whether repeated courses or alternative therapies are needed long term.
How patient selection criteria based on ApoE4 status impact the overall population eligible for Kisunla in clinical practice is not analyzed in depth. ApoE4 genotyping could restrict access, possibly excluding patients who might benefit but have two copies of the gene or different genetic profiles.
Competing evidence or uncertainty
Evidence from the pivotal clinical trial shows statistically significant slowing of cognitive decline, yet the clinical meaningfulness of this improvement remains debated. The magnitude of benefit is less than some might expect from a breakthrough Alzheimer’s therapy.
The safety concerns regarding ARIA are substantial. Although the frequency of serious ARIA events is lower in patients with none or one copy of ApoE4, it is not negligible. The requirement for extensive monitoring illustrates unresolved uncertainty about the risk profile.
There is limited publicly available evidence concerning long-term outcomes beyond 18 months of treatment, durability of benefit, or effects on survival and functional independence.
Some alternative approaches to Alzheimer’s therapy—both pharmaceutical and lifestyle-based—are under investigation; the positioning of donanemab within these evolving treatment paradigms is still emerging.
Evidence is insufficient to fully determine Kisunla’s effectiveness across diverse patient subgroups, healthcare systems, and in conjunction with other treatments.
Why it matters
Alzheimer’s disease presents a major and growing public health challenge due to aging populations and the lack of effective disease-modifying treatments. The authorization of Kisunla represents a regulatory milestone for a drug that targets a core pathological hallmark of Alzheimer’s—the amyloid beta plaques—and shows some potential to slow cognitive decline in early disease stages.
The scale and structure of treatment protocols, genetic testing requirements, and the monitoring of potentially serious side effects indicate this therapy will require careful management and resources in healthcare systems. Stakeholders must weigh the modest benefits against the risks and logistical complexities.
Understanding both the promise and limitations of Kisunla is critical for physicians, patients, caregivers, and policymakers to make informed decisions on treatment options and health system planning.
What to verify next
- Long-term follow-up data on cognitive, functional, and safety outcomes beyond 18 months in patients treated with Kisunla.
- Real-world effectiveness and safety data, especially related to ARIA incidence and management outside clinical trial settings.
- The experience and outcomes in patient subgroups excluded from initial authorization, such as those with two copies of ApoE4 or more advanced Alzheimer’s disease.
- Comparative effectiveness of Kisunla relative to other emerging Alzheimer’s treatments or combination therapies.
- Cost-effectiveness analyses including the burden and costs linked to the required genetic testing and repeated MRI monitoring.
- Patient and caregiver perspectives on the impact of Kisunla treatment, both benefits and side effects, on quality of life.
Readers should consult the original European Medicines Agency source for comprehensive details and official guidance regarding Kisunla, its use, and associated regulatory considerations.
Source & verification
Primary source: What's new · November 16, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EudraGMDP database
What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…

Antimicrobial resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2025
Evidence Dossier: Antimicrobial Resistance Trends in the EU/EEA 2025 Antimicrobial Resistance Trends in the EU/EEA: Evidence from the 2025 EARS-Net Report What is established…

Rapid risk assessment – Carbapenem-resistant Enterobacterales, fourth update
Evidence Dossier: Carbapenem-resistant Enterobacterales (CRE) in the EU/EEA – Latest Scientific Assessment What is established Carbapenem-resistant Enterobacterales (CRE), which include bacteria such as Klebsiella…